Table 1.
Baseline characteristics of rheumatoid arthritis patients who received abatacept and of the patients with high disease activity who received adalimumab or tocilizumab
| Abatacept | Adalimumab | Tocilizumab | ||||
|---|---|---|---|---|---|---|
| Disease activity at baseline | (in patients with HDA) | |||||
| ≤MDA | HDA | |||||
| (n = 86) | (n = 128) | p value | (n = 120) | (n = 97) | p valueb | |
| Age (years) | 64.1 ± 11.4 | 64.9 ± 10.9 | 0.64 | 57.3 ± 14.4 | 55.8 ± 13.8 | <0.001 |
| Gender (% female) | 82.6 | 80.5 | 0.725 | 82.5 | 78.4 | 0.761 |
| Disease duration (years) | 10.9 ± 10.1 | 13.0 ± 10.8 | 0.177 | 13.8 ± 10.6 | 10.7 ± 8.9 | 0.074 |
| Stage (I/II/III/IV %) | 11.6/26.7/34.9/26.7 | 10.2/12.5/41.4/35.9 | 0.052 | 12.5/15.0/30.0/42.5 | 13.4/23.7/24.7/38.1 | 0.097 |
| Class (I/II/III/IV %) | 11.6/45.3/41.9/1.2 | 3.2/45.3/48.4/3.1 | 0.071 | 8.3/50.8/37.5/3.3 | 12.4/44.3/43.3/0.0 | 0.069 |
| Prior use of biologics (%) | 51.2 | 52.3 | 0.89 | 32.5 | 62.9 | <0.001 |
| MTX use (%) | 51.2 | 48.4 | 0.781 | 76.7 | 36.1 | <0.001 |
| MTX dose (mg/week)a | 7.3 ± 2.5 | 7.2 ± 2.3 | 0.79 | 7.0 ± 1.9 | 7.9 ± 1.6 | 0.106 |
| Oral steroid use (%) | 52.3 | 54.7 | 0.779 | 60.8 | 71.9 | 0.041 |
| Oral steroid dose (mg/day)a | 4.2 ± 2.0 | 4.4 ± 2.3 | 0.643 | 5.2 ± 2.7 | 4.8 ± 2.1 | 0.181 |
| MMP-3 (ng/mL) | 226.9 ± 746.5 | 276.7 ± 271.6 | 0.568 | 335.1 ± 365.1 | 378.1 ± 307.8 | 0.066 |
| SJC, 0-28 | 2.7 ± 3.0 | 7.2 ± 5.9 | <0.001 | 7.9 ± 5.5 | 8.2 ± 5.9 | 0.357 |
| TJC, 0-28 | 2.7 ± 2.4 | 10.4 ± 7.2 | <0.001 | 9.2 ± 6.3 | 10.5 ± 7.6 | 0.345 |
| CRP (mg/dL) | 0.9 ± 1.3 | 3.1 ± 3.2 | <0.001 | 3.7 ± 3.3 | 3.7 ± 2.9 | 0.257 |
| GH, VAS 0–100 mm | 32.8 ± 20.8 | 70.4 ± 20.1 | <0.001 | 64.6 ± 20.6 | 61.5 ± 23.6 | 0.007 |
| DAS28-CRP | 3.2 ± 0.6 | 5.4 ± 0.9 | <0.001 | 5.3 ± 0.9 | 5.5 ± 1.0 | 0.656 |
Data are presented as mean ± standard deviation except when otherwise indicated
Stage Steinbrocker’s stages, Class Steinbrocker’s classes, MTX methotrexate, MMP-3 matrix metalloproteinase-3, SJC swollen joint count, TJC tender joint count, CRP c-reactive protein, GH general health, VAS visual analog scale, DAS28 Disease Activity Score in 28 joints
aMean among patients receiving the drug
bObtained from analysis of variance (ANOVA) between Abatacept (HDA), Adalimumab, and Tocilizumab groups